Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 16/20 | 0.83 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22480779 | 0.91 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL4496913 | 0.87 | MRGPRX4 (0.73) | MRGPRX4PTGER1KDM5AKDM4CKDM5B | |
| SCHEMBL4499409 | 0.86 | MRGPRX4 (0.63) | MRGPRX4 | |
| SCHEMBL4509663 | 0.84 | MRGPRX4 (0.62) | MRGPRX4KDM5AKDM4CKDM5BRXRA | |
| SCHEMBL4491985 | 0.84 | MRGPRX4 (0.62) | MRGPRX4PTGER1KDM5AKDM4CKDM5B | |
| SCHEMBL4510719 | 0.80 | MRGPRX4 (0.66) | MRGPRX4KDM5AKDM4CKDM5BRXRA | |
| SCHEMBL4505531 | 0.78 | MRGPRX4 (0.67) | MRGPRX4PTGER1CYP4F2CYP4A11 | |
| SCHEMBL4497112 | 0.77 | MRGPRX4 (0.72) | MRGPRX4KDM5AKDM4CKDM5BCYP4F2 | |
| SCHEMBL4510659 | 0.77 | MRGPRX4 (0.65) | MRGPRX4PTGER1RXRARXRBRXRG | |
| SCHEMBL4504876 | 0.75 | MRGPRX4 (0.49) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | MRGPRX4 1550/4885PTGER1 3083/4885KDM5A 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.